Kalaris Therapeutics (KLRS) risk factors

Item 1A of every Kalaris Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open KLRS in Gloom →

Kalaris Therapeutics' chart, financials and news, free in your browser.Open KLRS in Gloom →

FY2025 10-K risk factors
85 risks64 new98 dropped21 reworded
Kalaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing its lead candidate TH103 for retinal diseases like nAMD.
Filed Mar 17, 2026
FY2024 10-K risk factors
119 risks
Kalaris faces high-risk merger dynamics with AlloVir, including valuation adjustments, termination fees, and stockholder dilution. The company is heavily dependent on future financing, regulatory approvals, and competitive pressures in the biotech sector. Clinical-stage development carries substantial risks of failure, trial delays, and uncertain market acceptance.
Filed Mar 07, 2025